John Nicols - Codexis CEO and President and Director
| CDXS Stock | USD 2.68 0.06 2.19% |
CEO
Mr. John J. Nicols serves as President, Chief Executive Officer, Director of Codexis, Inc. Mr. Nicols brings to our board of directors his knowledge of Codexis as its President and Chief Executive Officer and his extensive prior management experience in the chemicals industry. Prior to that time, Mr. Nicols served in various capacities at Albemarle Corporationrationration, a public company focused on the development, manufacture and marketing of highly engineered specialty chemicals, since he joined that company in 1990. Mr. Nicols most recently served as its Senior Vice President, Strategic Development and Catalysts, from March 2012 to June 2012. Mr. Nicols previously served as its Vice President, Catalysts from January 2007 to February 2012, its Vice President, Fine Chemistry from June 2002 to December 2006, its Division Vice President, Global Flame Retardants business from February 1999 through June 2002 and its Asia Pacific Business Director for the Bromine Chemicals business, based in Tokyo, Japan, from 1995 to 1998. Prior to his time with Albemarle Corporationrationration, Mr. Nicols worked for three years in manufacturing and research and development for Hercules, Inc. Mr. Nicols has served on the board of directors of California Life Sciences Association, a nonprofit organization, since January 2014. In addition, Mr. Nicols has served on the board of directors of Solve MECFS Initiative, a nonprofit organization, since January 2015, and currently serves as chairperson and on the executive and nominating committees of that organization since 2012.
| Age | 60 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Address | 200 Penobscot Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 421 8100 |
| Web | https://www.codexis.com |
John Nicols Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Nicols against Codexis stock is an integral part of due diligence when investing in Codexis. John Nicols insider activity provides valuable insight into whether Codexis is net buyers or sellers over its current business cycle. Note, Codexis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Codexis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Nicols over three months ago Disposition of 35714 shares by John Nicols of Codexis at 1.97 subject to Rule 16b-3 | ||
John Nicols over six months ago Disposition of 35714 shares by John Nicols of Codexis at 4.0917 subject to Rule 16b-3 | ||
John Nicols over six months ago Acquisition by John Nicols of 35714 shares of Codexis at 1.97 subject to Rule 16b-3 | ||
John Nicols over six months ago Disposition of 35714 shares by John Nicols of Codexis at 1.97 subject to Rule 16b-3 |
Codexis Management Efficiency
The company has return on total asset (ROA) of (0.2554) % which means that it has lost $0.2554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8503) %, meaning that it created substantial loss on money invested by shareholders. Codexis' management efficiency ratios could be used to measure how well Codexis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 13.35 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (3.74). At this time, Codexis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 170.9 M in 2025, despite the fact that Non Current Assets Total are likely to grow to (75.7 M).Similar Executives
| Found 10 records | CEO Age | ||
| Mark Goldsmith | Revolution Medicines | 63 | |
| PharmD MBA | Century Therapeutics | N/A | |
| Adrian Gottschalk | Foghorn Therapeutics | 49 | |
| David Hung | Nuvation Bio | 63 | |
| Nadim Ahmed | Cullinan Oncology LLC | 57 | |
| Lynn MD | Lyell Immunopharma | 66 | |
| Paul Hastings | Nkarta Inc | 65 | |
| Markus MD | Monte Rosa Therapeutics | 53 | |
| Junyuan Wang | Nuvation Bio | 51 | |
| Jon Congleton | Mineralys Therapeutics, Common | 62 | |
Management Performance
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.26 |
Codexis Leadership Team
Elected by the shareholders, the Codexis' board of directors comprises two types of representatives: Codexis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Codexis. The board's role is to monitor Codexis' management team and ensure that shareholders' interests are well served. Codexis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Codexis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sriram MBA, Chief Officer | ||
| Georgia Erbez, Chief Officer | ||
| MBA Taylor, VP CFO | ||
| Asli Aras, VP Devel | ||
| Margaret JD, General Officer | ||
| John Schiffhauer, Senior Property | ||
| Stephen MBBS, CEO President | ||
| Rob Wilson, VP Enzymes | ||
| MS MBA, Chief Officer | ||
| Carrie McKim, Director Relations | ||
| John Nicols, CEO and President and Director | ||
| Karen FrechouArmijo, Senior Resources | ||
| Karl Schoene, Sr Operations | ||
| Robert MBA, Quality Development | ||
| Alison Moore, Chief Officer | ||
| Stefan Lutz, Senior Research |
Codexis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Codexis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 203.42 M | ||||
| Shares Outstanding | 82.84 M | ||||
| Shares Owned By Insiders | 2.44 % | ||||
| Shares Owned By Institutions | 79.82 % | ||||
| Number Of Shares Shorted | 3.05 M | ||||
| Price To Earning | (16.02) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Codexis Stock Analysis
When running Codexis' price analysis, check to measure Codexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codexis is operating at the current time. Most of Codexis' value examination focuses on studying past and present price action to predict the probability of Codexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Codexis' price. Additionally, you may evaluate how the addition of Codexis to your portfolios can decrease your overall portfolio volatility.